Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2003
09/18/2003US20030175693 HIV recombinant vaccine
09/18/2003US20030175683 In vitro system for replication of RNA-dependent RNA polymerase (RDRP) viruses
09/18/2003US20030175681 Inhibition of CMV infection and dissemination
09/18/2003US20030175312 Novel mutant allergens
09/18/2003US20030175311 A protein encoded by DNA sequence, for protecting poultry; veterinary medicine
09/18/2003US20030175309 Adjuvants for use in vaccines
09/18/2003US20030175308 Adjuvants for use in vaccines
09/18/2003US20030175304 Recombinant dimeric envelope vaccine against flaviviral infection
09/18/2003US20030175303 Production method of recombinant rotavirus structural proteins and vaccine composition
09/18/2003US20030175302 Avian pneumovirus vaccine
09/18/2003US20030175300 Cytotoxic Epstein-Barr virus T- cell epitopes are oligopeptides; vaccines
09/18/2003US20030175299 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections; stable oil-in-water emulsions, side effect reduction
09/18/2003US20030175298 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections
09/18/2003US20030175297 Cancer vaccines
09/18/2003US20030175296 Chimaeric hepadnavirus core antigen proteins
09/18/2003US20030175294 Heterologous fusion protein constructs comprising a Leishmania antigen
09/18/2003US20030175293 Choline binding proteins for anti-pneumococcal vaccines
09/18/2003US20030175292 Compositions and methods for generating an immune response
09/18/2003US20030175291 Multiple and multivalent DNA vaccines in ovo
09/18/2003US20030175290 Molecular antigen array
09/18/2003US20030175289 TIE ligands
09/18/2003US20030175288 Polypeptides used for induction of cytotoxic T lymphocytes or activation of human leukocyte antigens (HLA), administered as anticarcinogenic vaccines; immunology
09/18/2003US20030175287 Fusion proteins comprising Pathogen Associated Molecular Patterns (PAMPs), immunostimulants and antigen or immunogens, administered to activate lymphocytes; immunology
09/18/2003US20030175285 Major histocompatibility complex ligands, comprising proteins, peptides, epitopes, polypeptides, mimetics or lipopeptides, used as vaccines
09/18/2003US20030175283 Synergystic mixtures of mint oils, terpenes and ajuvants used as bactericides
09/18/2003US20030175281 Monoclonal antibodies that preferntially bind to proteins having cytolysis and immunogenic activity
09/18/2003US20030175280 Antagonists to chaperonin 10
09/18/2003US20030175277 Administering mixtures of antigens and phospholipase inhibitors as antitumor or anticarcinogenic agents
09/18/2003US20030175276 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents
09/18/2003US20030175274 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents
09/18/2003US20030175273 Monoclonal antibodies which preferentially bind to chemokine receptors, used for immunotherapy, as antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system disorders or antiallergens
09/18/2003US20030175272 Re-activated T-cells for adoptive immunotherapy
09/18/2003US20030175271 VEGF activity inhibitor
09/18/2003US20030175270 Suppression of Janus kinase and signal transducers and acitavators of transcription (JAK/STAT), by administering monoclonal antibodies; immunology
09/18/2003US20030175269 Light and heavy chain peptides, used as antagonists of CD antigen or membrane proteins, for prophylaxis of autoimmune diseases
09/18/2003US20030175267 Method for the treatment of inflammatory joint disease
09/18/2003US20030175265 Chandra: a novel Th1-specific gene
09/18/2003US20030175252 Therapeutic compounds for ovarian cancer
09/18/2003US20030175250 Isolated peptides which bind to HLA molecules and uses thereof
09/18/2003US20030175247 For activating lymphocytes (CD-8 antigens) in response to metastatic cancer; tumor associated antigens; major histocompatibility complex; cryopreservation; prostate specific antigen
09/18/2003US20030175243 Blocking receptor binding; gene therapy; gastrin releasing peptide
09/18/2003US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy
09/18/2003US20030175206 Administering large liposomes to retend radioactive decay intermediates
09/18/2003DE20121877U1 Module for suppressing leukocyte activity, useful e.g. in association with heart-lung machines, comprises a carrier linked to a ligand specific for the leukocyte receptor
09/18/2003CA2813780A1 Genetic products differentially expressed in tumors and use thereof
09/18/2003CA2518586A1 Fuel additive
09/18/2003CA2480962A1 Immunogenicity of glucan binding protein
09/18/2003CA2479021A1 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
09/18/2003CA2478846A1 Use of mixtures of lipopeptides for vaccine production
09/18/2003CA2478631A1 Method of inducing an enhanced immune response against hiv
09/18/2003CA2478604A1 Cancer-linked gene as target for chemotherapy
09/18/2003CA2478593A1 Cancer-linked gene as target for chemotherapy
09/18/2003CA2478413A1 Genetic products differentially expressed in tumors and use thereof
09/18/2003CA2478371A1 Compositions and methods for generating an immune response
09/18/2003CA2478369A1 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
09/18/2003CA2478346A1 Specific ab1'-antibodies against tumour-associated antigen ca 125
09/18/2003CA2478338A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
09/18/2003CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
09/18/2003CA2478239A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
09/18/2003CA2478177A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
09/18/2003CA2478169A1 Human antibodies specific to kdr and uses thereof
09/18/2003CA2478102A1 Antigens and their use as diagnostics and vaccines against species of plasmodium
09/18/2003CA2478029A1 Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
09/18/2003CA2477780A1 Methods of enhancing immune induction involving mda-7
09/18/2003CA2477675A1 Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein
09/18/2003CA2477273A1 Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections
09/18/2003CA2476767A1 Use of the mal protein as a tumour marker
09/17/2003EP1344826A1 Materials comprising and methods of preparation and use for ribosome - inactivating proteins
09/17/2003EP1344064A2 Compositions and methods relating to prostate specific genes and proteins
09/17/2003EP1343912A2 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
09/17/2003EP1343900A2 Oxidoreductases
09/17/2003EP1343895A2 Streptococcus pyogenes antigens and corresponding dna fragments
09/17/2003EP1343894A1 Aopb gene, protein, homologs, fragments and variants thereof, and their use for cell surface display
09/17/2003EP1343888A2 Regulation of human chemokine-like receptor
09/17/2003EP1343886A2 Compositions and methods for the therapy and diagnosis of lung cancer
09/17/2003EP1343871A2 Isolation and use of solid tumor stem cells
09/17/2003EP1343826A1 Polysaccharide compound having immune stimulating activity
09/17/2003EP1343822A2 Means for the diagnosis and therapy of ctcl
09/17/2003EP1343820A1 Human anti-epidermal growth factor receptor single-chain antibodies
09/17/2003EP1343819A1 Hla-a2.1 binding peptides and their uses
09/17/2003EP1343814A2 Immunogenic glycopeptides, screening, preparation and uses
09/17/2003EP1343527A2 Adjuvant combination formulations
09/17/2003EP1343526A2 Vaccine
09/17/2003EP1343525A2 IMPROVED i MYCOPLASMA HYOPNEUMONIAE /i BACTERIN VACCINE
09/17/2003EP1343524A1 Vaccine based on a cellular penetration factor from an apicomplexan parasite
09/17/2003EP1343517A2 Survical promoting ncam binding and ncam ligand biding compounds
09/17/2003EP1343514A2 Chlamydia pmp proteins, gene sequences and uses thereof
09/17/2003EP1343476A2 Preparation of large liposomes by infusion into peg
09/17/2003EP1091763B1 Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters
09/17/2003EP1033973B1 Encapsulation method
09/17/2003EP1003560B1 Radioprotectant for peptides labeled with radioisotope
09/17/2003EP0972782B1 Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
09/17/2003EP0914114B1 Methods of treating type i hypersensitivity using monophosphoryl lipid a
09/17/2003EP0842428B1 Process for producing gm2 specific antibodies
09/17/2003EP0831937B1 Immunological combination compositions and methods
09/17/2003EP0792165B1 Immunogenic compositions
09/17/2003EP0697888B1 Conserved motif of hepatitis c virus e2/ns1 region
09/17/2003EP0669988B1 Angiogenesis inhibitory antibodies
09/17/2003EP0571613B1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
09/17/2003EP0478664B1 Vector-mediated genomic insertion and expression of dna in bcg
1 ... 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 ... 1823